Rifampin
NDC 55695-034
Product Information
Rifampin is a ANDA-approved product labeled by Department Of State Health Services, Pharmacy Branch. This medication is a rifamycin antibiotic used to prevent and treat tuberculosis and other infections. It is supplied as a orange product. This product entry covers the primary NDC 55695-034 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
20 MM
RIFAMPIN;150;VP;015
RIFAMPIN;300;VP;018
Code Structure Chart
Product Details
What is NDC 55695-034?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- RIFAMPIN (UNII: VJT6J7R4TR)
- RIFAMPIN (UNII: VJT6J7R4TR) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)
- SODIUM LAURYL SULFATE (UNII: 368GB5141J)
- TALC (UNII: 7SEV7J4R1U)
- STARCH, CORN (UNII: O8232NY3SJ)
- SILICON DIOXIDE (UNII: ETJ7Z6XBU4)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- AMMONIA (UNII: 5138Q19F1X)
- ISOPROPYL ALCOHOL (UNII: ND2M416302)
- BUTYL ALCOHOL (UNII: 8PJ61P6TS3)
- SHELLAC (UNII: 46N107B71O)
- PROPYLENE GLYCOL (UNII: 6DC9Q167V3)
- DIMETHICONE (UNII: 92RU3N3Y1O)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
- FD&C BLUE NO. 1 (UNII: H3R47K3TBD)
- FD&C RED NO. 40 (UNII: WZB9127XOA)
- GELATIN (UNII: 2G86QN327L)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 198201 - rifAMPin 150 MG Oral Capsule
- RxCUI: 198201 - rifampin 150 MG Oral Capsule
- RxCUI: 198202 - rifAMPin 300 MG Oral Capsule
- RxCUI: 198202 - rifampin 300 MG Oral Capsule
* Please review the full disclaimer at the bottom of this page.